RxDoctor Payments Data

Shawn Hobbs, OD

Optometrist · Henrico, VANPI 1295720019

Payments from drug & device makers

$1,599in general payments, 2019–2025

Across 16 payments — averaging $99.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$447
  • Tarsus Pharmaceuticals, Inc.$144
  • Biotissue Holdings Inc.$129
  • Optos, Inc.$123
  • Topcon Healthcare, Inc.$122
  • Amgen$122
  • plus $512 from 6 others

What the payments were for

  • Food & beverage$1,47692%
  • Entertainment$1238%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,599 in reported general payments places this provider in the 65th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$218,027
Medicare patients
1,089
Services billed
2,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost193$85,768
RestasisCyclosporine42$52,370
Latanoprost2,355$17,667
CombiganBrimonidine Tartrate/Timolol27$12,471
RhopressaNetarsudil Mesylate19$8,460
Timolol Maleate984$7,519
Travoprost26$6,561
Brimonidine Tartrate574$4,632
Prednisolone Acetate93$4,307
Alphagan PBrimonidine Tartrate11$3,168
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$3,114
Dorzolamide Hcl185$2,995
Brinzolamide14$2,953
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat132$1,518
TafluprostTafluprost/Pf11$1,434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$80$153,776273 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Henrico

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →